Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Am J Trop Med Hyg ; 102(6): 1404-1410, 2020 06.
Artículo en Inglés | MEDLINE | ID: mdl-32228796

RESUMEN

Following the halt of mass drug administration (MDA) for lymphatic filariasis (LF), the WHO recommends at least 4 years of post-treatment surveillance (PTS) to confirm that transmission recrudescence or importation does not occur. The primary means of evaluation during PTS is repeated transmission assessment surveys (TASs) conducted at 2- to 3-year intervals after TAS-1 stop-MDA surveys. This study reports the results of TAS-2 and TAS-3 surveys in Plateau and Nasarawa states (pop. 6.9 million) of Nigeria divided into a minimum of seven evaluation units (EUs) per TAS. A total of 26,536 first- and second-year primary school children (approximately 6-7 years old) were tested for circulating filarial antigen (CFA) between 2014 and 2017. Of 12,313 children tested in TAS-2 surveys, only five (0.04%) were CFA positive, with no more than two positive samples from any one EU, which was below the critical value of 20 per EU. Of 14,240 children tested in TAS-3 surveys, none (0%) were CFA positive. These results indicate that LF transmission remains below sustainable transmission levels and suggest that elimination of transmission has been achieved in Plateau and Nasarawa, Nigeria.


Asunto(s)
Albendazol/uso terapéutico , Filariasis Linfática/epidemiología , Filariasis Linfática/prevención & control , Ivermectina/uso terapéutico , Administración Masiva de Medicamentos , Vigilancia de la Población , Albendazol/administración & dosificación , Antihelmínticos/administración & dosificación , Antihelmínticos/uso terapéutico , Niño , Preescolar , Femenino , Filaricidas/uso terapéutico , Humanos , Ivermectina/administración & dosificación , Masculino , Nigeria/epidemiología , Estudios Retrospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA